Townsend Asset Management Corp NC ADV Cuts Stake in Becton, Dickinson and Company (NYSE:BDX)

Townsend Asset Management Corp NC ADV lessened its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 7.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 995 shares of the medical instruments supplier’s stock after selling 75 shares during the quarter. Townsend Asset Management Corp NC ADV’s holdings in Becton, Dickinson and Company were worth $240,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the business. Fermata Advisors LLC boosted its holdings in shares of Becton, Dickinson and Company by 12.0% during the 1st quarter. Fermata Advisors LLC now owns 1,238 shares of the medical instruments supplier’s stock worth $306,000 after purchasing an additional 133 shares during the last quarter. DLK Investment Management LLC boosted its stake in Becton, Dickinson and Company by 7.8% during the first quarter. DLK Investment Management LLC now owns 18,174 shares of the medical instruments supplier’s stock worth $4,497,000 after buying an additional 1,320 shares during the last quarter. Security National Bank grew its holdings in Becton, Dickinson and Company by 18.3% in the 1st quarter. Security National Bank now owns 408 shares of the medical instruments supplier’s stock valued at $101,000 after buying an additional 63 shares in the last quarter. Mcdonald Partners LLC increased its stake in shares of Becton, Dickinson and Company by 1.1% in the 1st quarter. Mcdonald Partners LLC now owns 5,966 shares of the medical instruments supplier’s stock worth $1,476,000 after acquiring an additional 63 shares during the last quarter. Finally, Kingswood Wealth Advisors LLC purchased a new position in shares of Becton, Dickinson and Company during the 1st quarter worth $229,000. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Becton, Dickinson and Company Trading Down 1.4 %

BDX opened at $240.45 on Tuesday. Becton, Dickinson and Company has a 52 week low of $218.75 and a 52 week high of $262.23. The company has a quick ratio of 1.36, a current ratio of 1.85 and a debt-to-equity ratio of 0.70. The business has a fifty day simple moving average of $237.14 and a 200-day simple moving average of $235.16. The firm has a market cap of $69.49 billion, a P/E ratio of 52.96, a P/E/G ratio of 1.79 and a beta of 0.42.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 EPS for the quarter, beating analysts’ consensus estimates of $3.31 by $0.19. The company had revenue of $4.99 billion during the quarter, compared to analysts’ expectations of $5.08 billion. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. Becton, Dickinson and Company’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same period last year, the business posted $2.96 EPS. On average, equities analysts expect that Becton, Dickinson and Company will post 13.11 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on BDX shares. Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and upped their price objective for the company from $255.00 to $275.00 in a report on Tuesday, October 1st. Raymond James cut their price target on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a report on Friday, August 2nd. Stifel Nicolaus lifted their price target on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a research report on Friday, July 26th. Evercore ISI increased their price objective on Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Finally, StockNews.com upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Nine research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Becton, Dickinson and Company has a consensus rating of “Buy” and a consensus price target of $282.63.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.